Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001953530 | SCV002241882 | pathogenic | not provided | 2021-11-10 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with GFM1-related conditions. This variant is present in population databases (rs763423294, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Trp30Serfs*10) in the GFM1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GFM1 are known to be pathogenic (PMID: 16632485, 17160893). |
Revvity Omics, |
RCV003146413 | SCV003834574 | likely pathogenic | Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 | 2021-12-29 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003146413 | SCV004199361 | likely pathogenic | Hepatoencephalopathy due to combined oxidative phosphorylation defect type 1 | 2022-09-01 | criteria provided, single submitter | clinical testing |